49Z Stock Chart & Stats
€1.19
-€0.02(-1.97%)
At close: 4:00 PM EDT
€1.19
-€0.02(-1.97%)
Day’s Range― - ―
52-Week Range€1.19 - €3.01
Previous CloseN/A
Volume0.00
Average Volume (3M)653.00
Market Cap
€106.82M
Enterprise Value€1.20K
Total Cash (Recent Filing)€627.60M
Total Debt (Recent Filing)€266.40M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 11, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.89
Shares Outstanding69,074,900
10 Day Avg. Volume367
30 Day Avg. Volume653
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.24
Revenue Forecast (FY)€140.11M
Bulls Say, Bears Say
Bulls Say
Structural Margin ImprovementThe sharp gross-margin expansion, lower operating expenses and positive adjusted EBITDA indicate improved product mix and cost discipline. If sustained, these changes can strengthen the earnings model beyond a single quarter.
Long-Term Contracted RevenueThe decade-long Scienion supply and license agreements add contractual revenue visibility and deepen customer relationships. This supports planning and utilization of BICO’s platforms, although the license component is not necessarily recurring.
Improved Balance Sheet FlexibilityThe move to net cash materially improves financial flexibility and reduces immediate refinancing pressure. A stronger liquidity position can support product development, selective bolt-on investments and the company’s ability to absorb operational volatility.
Bears Say
Deeply Negative ProfitabilityDespite better gross margins, BICO has not yet converted revenue into sustainable bottom-line profits. Persistent operating losses can consume balance-sheet capacity, increase dependence on restructuring and raise future dilution or re-leveraging risk.
Weak Self-Funding CapacityNegative operating cash flow and slightly negative free cash flow show that current operations are not reliably funding investment and obligations. Working-capital volatility, especially rising receivables and inventories, could constrain flexibility even with cash reserves.
Project Execution And Demand RiskExecution problems in project-based automation can create lumpy revenue, cost overruns and customer delays. Weak academic funding and extended purchasing cycles further reduce visibility and may limit conversion of the broader automation opportunity.
BICO Group AB Class B News
49Z FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was €1.19 and its highest was €3.01 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is €106.82M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Nov 11, 2026 which is in 82 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Aug 19, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.064 by €0.018.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.07.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.064. Following the earnings report the stock price went down -2.391%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in DE:49Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
49Z Company Deck
49Z Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call combined meaningful operational and financial improvements (strong product launches, a large long-term license/supply agreement, substantial gross margin expansion, improved adjusted EBITDA margin, reductions in operating expenses and a stronger balance sheet) with persistent operational and market headwinds (project execution issues in the U.S. project business, negative operating cash flow driven by working capital movements, soft North American/academic end markets and longer sales cycles for large automation projects). Progress on commercialization and profitability is clear, but execution risk in project-based automation and short-term cash-flow/working-capital pressure leave mixed near-term visibility.View all DE:49Z earnings summariesTechnical Analysis
Vitrolife AB
―
BONESUPPORT HOLDING AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
OssDsign AB
―